Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter A Ljubenkov

Showing results (1-10 of 33) with videos related to

Pageof 4
Sort By:
Advances in Experimental Medicine and Biology|January 12, 2021
FTLD Treatment: Current Practice and Future PossibilitiesPeter A Ljubenkov, Adam L Boxer
Seminars in Neurology|September 20, 2016
DementiaPeter A Ljubenkov, Michael D Geschwind
Focus (American Psychiatric Publishing)|January 25, 2020
A Clinical Guide to Frontotemporal DementiasPeter A Ljubenkov, Bruce L Miller
Nature Medicine|May 17, 2023
Silencing tau to treat early Alzheimer's diseasePeter A Ljubenkov, Gil D Rabinovici
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|July 18, 2020
Four-Repeat Tauopathies: Current Management and Future TreatmentsLawren VandeVrede, Peter A Ljubenkov, Julio C Rojas, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|September 9, 2025
Plasma lipidome dysregulation in frontotemporal dementia reveals shared, genotype-specific, and severity-linked alterationsYohannes A Ambaw, Peter A Ljubenkov, Shubham Singh, et al.
Frontiers in Neurology|July 11, 2022
Case Report: Novel <i>CSF1R</i> Variant in a Patient With Behavioral Variant Frontotemporal Dementia Syndrome With Prodromal Repetitive Scratching BehaviorAdit Friedberg, Eliana Marisa Ramos, Zhongan Yang, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|October 19, 2020
Symptomatic amyloid-related imaging abnormalities in an APOE ε4/ε4 patient treated with aducanumabLawren VandeVrede, Daniel M Gibbs, Mary Koestler, et al.
Acta Neuropathologica|February 13, 2025
Correction to: Co-pathology may impact outcomes of amyloid-targeting treatments: clinicopathological results from two patients treated with aducanumabLawren VandeVrede, Renaud La Joie, Sheena Horiki, et al.
Acta Neuropathologica|September 19, 2023
Co-pathology may impact outcomes of amyloid-targeting treatments: clinicopathological results from two patients treated with aducanumabLawren VandeVrede, Renaud La Joie, Sheena Horiki, et al.
Pageof 4

Showing results (1-10 of 33) with videos related to

Sort By:
Pageof 4
Advances in Experimental Medicine and Biology|January 12, 2021
FTLD Treatment: Current Practice and Future PossibilitiesPeter A Ljubenkov, Adam L Boxer
Seminars in Neurology|September 20, 2016
DementiaPeter A Ljubenkov, Michael D Geschwind
Focus (American Psychiatric Publishing)|January 25, 2020
A Clinical Guide to Frontotemporal DementiasPeter A Ljubenkov, Bruce L Miller
Nature Medicine|May 17, 2023
Silencing tau to treat early Alzheimer's diseasePeter A Ljubenkov, Gil D Rabinovici
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|July 18, 2020
Four-Repeat Tauopathies: Current Management and Future TreatmentsLawren VandeVrede, Peter A Ljubenkov, Julio C Rojas, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|September 9, 2025
Plasma lipidome dysregulation in frontotemporal dementia reveals shared, genotype-specific, and severity-linked alterationsYohannes A Ambaw, Peter A Ljubenkov, Shubham Singh, et al.
Frontiers in Neurology|July 11, 2022
Case Report: Novel <i>CSF1R</i> Variant in a Patient With Behavioral Variant Frontotemporal Dementia Syndrome With Prodromal Repetitive Scratching BehaviorAdit Friedberg, Eliana Marisa Ramos, Zhongan Yang, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|October 19, 2020
Symptomatic amyloid-related imaging abnormalities in an APOE ε4/ε4 patient treated with aducanumabLawren VandeVrede, Daniel M Gibbs, Mary Koestler, et al.
Acta Neuropathologica|February 13, 2025
Correction to: Co-pathology may impact outcomes of amyloid-targeting treatments: clinicopathological results from two patients treated with aducanumabLawren VandeVrede, Renaud La Joie, Sheena Horiki, et al.
Acta Neuropathologica|September 19, 2023
Co-pathology may impact outcomes of amyloid-targeting treatments: clinicopathological results from two patients treated with aducanumabLawren VandeVrede, Renaud La Joie, Sheena Horiki, et al.
Pageof 4